The evidence-based treatment of AIDS-related non-Hodgkin's lymphoma

Cancer Treat Rev. 2004 May;30(3):249-53. doi: 10.1016/j.ctrv.2003.12.004.

Abstract

As we enter the third decade of the AIDS epidemic, it is apparent that a large number of cancers are more common in people with the human immunodeficiency virus type 1 (HIV). Non-Hodgkin's lymphoma (NHL) remains the second most common tumour in such patients. At the onset of the epidemic, dose-intense combination regimens were used but these were quickly abandoned in favour of dose-modified strategies because of difficulties in tolerating aggressive chemotherapy in the presence of underlying immunosuppression. With the improvements in supportive care including more effective anti-retroviral therapies, colony-stimulating factors and prophylaxis against opportunistic infections, we are returning to the traditional chemotherapeutic approaches similar to those utilised in the non-HIV infected individual including infusional regimens. In this review, we discuss the evidence for choosing particular therapies in patients with AIDS-related NHL.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Administration, Oral
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antiretroviral Therapy, Highly Active / methods*
  • Drug Therapy, Combination
  • Evidence-Based Medicine
  • Female
  • Humans
  • Infusions, Intravenous
  • Lymphoma, AIDS-Related / diagnosis
  • Lymphoma, AIDS-Related / drug therapy*
  • Lymphoma, AIDS-Related / epidemiology*
  • Lymphoma, Non-Hodgkin / diagnosis
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / epidemiology*
  • Male
  • Middle Aged
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Risk Assessment
  • Severity of Illness Index
  • Survival Analysis
  • Treatment Outcome
  • United Kingdom / epidemiology